Work

Preliminary Safety and Efficacy Of IPI-145, a Potent Inhibitor Of Phosphoinositide-3-Kinase-δ,γ, In Patients With Chronic Lymphocytic Leukemia

Year: 2013

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v122.21.677.677

Authors: Ian Flinn, Manish Patel, Brad S. Kahl, Steven M. Horwitz, Francine M. Foss, Yasuhiro Oki, Pierluigi Porcu, Jennifer Sweeney, Kerstin Allen, Kerrie Faia, Patricia Harris, Joi Dunbar, Howard M. Stern, Patrick Kelly, Susan O'Brien

Institutions: Sarah Cannon, University of Wisconsin–Madison, Memorial Sloan Kettering Cancer Center, Yale Cancer Center, Yale University, The University of Texas MD Anderson Cancer Center, The Ohio State University Wexner Medical Center, Infinity Pharmaceuticals (United States)

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2276310429

FWCI: 4.096

Cites:

Cited by: 28

Related to: 10